Article Text

other Versions

PDF
Protein C Inhibitor regulates Hepatocyte Growth Factor Activator-mediated Liver Regeneration in Mice
  1. Takashi Hamada (hamadataka4{at}aol.com)
  1. Department of Molecular Pathobiology,Mie University Graduate School of Medicine, Japan
    1. Haruhiko Kamada
    1. Department of Molecular Pathobiology, Mie University Graduate School of Medicine, Japan
      1. Tatsuya Hayashi
      1. Department of Molecular Pathobiology, Mie University Graduate School of Medicine, Japan
        1. Junji Nishioka
        1. Department of Molecular Pathobiology, Mie University Graduate School of Medicine, Japan
          1. Esteban C Gabazza
          1. Department of Molecular Pathobiology, Mie University Graduate School of Medicine, Japan
            1. Shuji Isaji
            1. Department of Hepatobiliary Pancreatic Surgery and Breast Surgery, Mie University, Japan
              1. Shinji Uemoto
              1. Department of Hepatobiliary Pancreatic Surgery and Breast Surgery, Mie University Graduate School, Japan
                1. Koji Suzuki (suzuki{at}doc.medic.mie-u.ac.jp)
                1. Department of Molecular Pathobiology, Mie University Graduate School of Medicine, Japan

                  Abstract

                  Background: We recently reported that human protein C inhibitor (PCI), a major inhibitor of activated protein C (APC), inhibits hepatocyte growth factor activator (HGFA) by forming HGFA-PCI complexes in vitro. In this study, we evaluated whether PCI regulates HGFA-mediated liver regeneration in a human PCI gene transgenic (hPCI-Tg) mouse model. Methods and Results: After partial hepatectomy in hPCI-Tg and wild-type (WT) mice, the degree of liver regeneration, protein and mRNA expression of HGFA, proHGF activation, plasma levels of PCI and HGFA-PCI complex, and other markers were evaluated in the remnant liver. We also evaluated the effect of anti-human PCI antibody on liver regeneration. Liver regeneration significantly decreased in hPCI-Tg mice compared to WT mice. HGFA mRNA levels in naive and remnant livers after hepatectomy were the same in both WT and hPCI-Tg mice; however, plasma HGFA levels and HGF activation in the liver were lower in hPCI-Tg than in WT mice. There was no difference in plasma levels of transaminases and inflammatory cytokines. However, sinusoidal congestion and bleeding were detected and the serum hyarulonic acid level was elevated in hPCI-Tg mice, indicating that human PCI aggravates sinusoidal injury by inhibiting the cytoprotective effect of APC. APC decreased thrombin-induced IL-6 production in isolated hepatic nonparenchymal cells (NPCs) in vitro. This impaired liver regeneration was reversed by anti-human PCI antibody treatment in vivo. Conclusion: PCI regulates liver regeneration after hepatectomy by forming HGFA-PCI complex and aggravates hepatic NPCs injury by inhibiting the cytoprotective effect of APC. Anti-PCI antibody treatment may be a novel therapy for improving liver regeneration.

                  • HGFA-PCI complex
                  • Hepatocyte Growth Factor Activator (HGFA)
                  • Protein C inhibitor (PCI)
                  • hPCI transgenic mice
                  • liver regeneration

                  Statistics from Altmetric.com

                  Request permissions

                  If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.